The DOI matches its Crossref record; 36 of the 36 references it cites were found in a registry or an index.
Low‐dose prednisolone in addition to the initial disease‐modifying antirheumatic drug in patients with early active rheumatoid arthritis reduces joint destruction and increases the remission rate: A two‐year randomized trial
Abstract
Objective: To assess the efficacy of low‐dose prednisolone on joint damage and disease activity in patients with early rheumatoid arthritis (RA). Methods: At the start of their initial treatment with a disease‐modifying antirheumatic drug (DMARD), patients with early (duration ≤1 year) active RA were randomly assigned to receive either 7.5 mg/day prednisolone or no prednisolone for 2 years. Radiographs of the hands and feet were obtained at baseline and after 1 and 2 years and scored according to the Sharp score as modified by van der Heijde. Remission was defined as a Disease Activity Score in 28 joints of <2.6. Bone mineral density was measured by dual x‐ray absorptiometry at baseline and after 2 years. Results: Of the 250 patients included, 242 completed the study and 225 had radiographs available both at baseline and at 2 years. At 2 years, the median and interquartile range (IQR) change in total Sharp score was lower in the prednisolone group than in the no‐prednisolone group (1.8 [IQR 0.5–6.0] versus 3.5 [IQR 0.5–10];P= 0.019). In the prednisolone group, there were fewer newly eroded joints per patient after 2 years (median 0.5 [IQR 0–2] versus 1.25 [IQR 0–3.25];P= 0.007). In the prednisolone group, 25.9% of patients had radiographic progression beyond the smallest detectable difference compared with 39.3% of patients in the no‐prednisolone group (P= 0.033). At 2 years, 55.5% of patients in the prednisolone group had achieved disease remission, compared with 32.8% of patients in the no‐prednisolone group (P= 0.0005). There were few adverse events that led to withdrawal. Bone loss during the 2‐year study was similar in the 2 treatment groups. Conclusion: Prednisolone at 7.5 mg/day added to the initial DMARD retarded the progression of radiographic damage after 2 years in patients with early RA, provided a high remission rate, and was well tolerated. Therefore, the data support the use of low‐dose prednisolone as an adjunct to DMARDs in early active RA.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Arnett, F. C., Edworthy, S. M., Bloch, D. A., Mcshane, D. J., Fries, J. F., Cooper, N. S., Healey, L. A., Kaplan, S. R., Liang, M. H., Luthra, H. S., et al. (1988) · Arthritis & Rheumatism · doi:10.1002/art.1780310302 · Cited by 19,752
Revised Criteria for the Classification of Rheumatoid Arthritis
Arnett, F. C. (1990) · Orthopaedic Nursing · doi:10.1097/00006416-199003000-00011 · Cited by 7,723
Prevoo, M. L. L., Van'T Hof, M. A., Kuper, H. H., Van Leeuwen, M. A., Van De Putte, L. B. A., & Van Riel, P. L. C. M. (1995) · Arthritis & Rheumatism · doi:10.1002/art.1780380107 · Cited by 6,243
Hench, P. S., Kendall, E. C., Slocumb, C. H., & Polley, H. F. (1949) · Mayo Clinic Proceedings · doi:10.1016/s0025-6196(24)00526-3 · Cited by 1,179
Boers, M., Verhoeven, A. C., Markusse, H. M., van de Laar, M. A., Westhovens, R., van Denderen, J. C., van Zeben, D., Dijkmans, B. A., Peeters, A. J., Jacobs, P., et al. (1997) · The Lancet · doi:10.1016/s0140-6736(97)01300-7 · Cited by 1,073
Self-citationThe Effect of Glucocorticoids on Joint Destruction in Rheumatoid Arthritis
Kirwan, J. R. (1995) · New England Journal of Medicine · doi:10.1056/nejm199507203330302 · Cited by 817
Landewé, R. B. M., Boers, M., Verhoeven, A. C., Westhovens, R., van de Laar, M. A. F. J., Markusse, H. M., van Denderen, J. C., Westedt, M. L., Peeters, A. J., Dijkmans, B. A. C., et al. (2002) · Arthritis & Rheumatism · doi:10.1002/art.10083 · Cited by 612
Self-citationFactors predicting response to treatment in rheumatoid arthritis: The importance of disease duration
Anderson, J. J., Wells, G., Verhoeven, A. C., & Felson, D. T. (2000) · Arthritis & Rheumatism · doi:10.1002/1529-0131(200001)43:1<22::aid-anr4>3.0.co;2-9 · Cited by 503
van Everdingen, A. A., Jacobs, J. W. G., Siewertsz van Reesema, D. R., & Bijlsma, J. W. J. (2002) · Annals of Internal Medicine · doi:10.7326/0003-4819-136-1-200201010-00006 · Cited by 489
The links between joint damage and disability in rheumatoid arthritis
Scott, D. L., Pugner, K., Kaarela, K., Doyle, D. V., Woolf, A., Holmes, J., & Hieke, K. (2000) · Rheumatology · doi:10.1093/rheumatology/39.2.122 · Cited by 473
Ekdahl, C., Eberhardt, K., Andersson, S. I., & Svensson, B. (1988) · Scandinavian Journal of Rheumatology · doi:10.3109/03009748809098795 · Cited by 467
Self-citationHeijde, D. M. F. M. V. D., Leeuwen, M. A. V., Riel, P. L. C. M. V., Koster, A. M., Hof, M. A. V., Rijswijk, M. H. V., & Putte, L. B. A. V. D. (1992) · Arthritis & Rheumatism · doi:10.1002/art.1780350105 · Cited by 447
PREVOO, M. L. L., VAN GESTEL, A. M., VAN THOF, M. A., VAN RIJSWIJK, M. H., VAN DE PUTTE, L. B. A., & VAN RIEL, P. L. C. M. (1996) · Rheumatology · doi:10.1093/rheumatology/35.11.1101 · Cited by 373
Symmons, D. P. M., Jones, M., Scott, D. L., & Prior, P. (1998) · PubMed · Cited by 319
Bruynesteyn, K., Boers, M., Kostense, P., van der Linden, S., & van der Heijde, D. (2005) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2003.018457 · Cited by 295
Self-citationWelsing, P. M. J., Landewé, R. B. M., Van Riel, P. L. C. M., Boers, M., Van Gestel, A. M., Van Der Linden, S., Swinkels, H. L., & Van Der Heijde, D. M. F. M. (2004) · Arthritis & Rheumatism · doi:10.1002/art.20350 · Cited by 271
Self-citationTreating rheumatoid arthritis early: A window of opportunity?
O'Dell, J. R. (2002) · Arthritis & Rheumatism · doi:10.1002/art.10092 · Cited by 266
Mulherin, D. (1996) · Rheumatology · doi:10.1093/rheumatology/35.12.1263 · Cited by 226
Hickling, P., Jacoby, R. K., & Kirwan, J. R. (1998) · Rheumatology · doi:10.1093/rheumatology/37.9.930 · Cited by 201
Leeuwen, M. A. V., van Rijswijk, M. H., Sluiter, W. J., van Riel, P. L., Kuper, I. H., van de Putte, L. B., Pepys, M. B., & Limburg, P. C. (1997) · PubMed · Cited by 190
Sokka, T., & Pincus, T. (2003) · Arthritis & Rheumatism · doi:10.1002/art.10817 · Cited by 180
Capell, H. A., Madhok, R., Hunter, J. A., Porter, D., Morrison, E., Larkin, J., Thomson, E. A., Hampson, R., & Poon, F. W. (2004) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2003.014050 · Cited by 160
(1959) · Annals of the Rheumatic Diseases · doi:10.1136/ard.18.3.173 · Cited by 139
Low dose prednisone therapy in rheumatoid arthritis: a double blind study.
Harris, E. D., Emkey, R. D., Nichols, J. E., & Newberg, A. H. (1983) · PubMed · Cited by 127
van der Heijde, D. M. F. M., Boonen, A. E. R. C. H., Boers, M., Kostense, P. J., & van der Linden, S. (1999) · Rheumatology · doi:10.1093/rheumatology/38.12.1213 · Cited by 125
Self-citationGøtzsche, P. C., & Johansen, H. (1998) · BMJ · doi:10.1136/bmj.316.7134.811 · Cited by 118
Glucocorticoids and rheumatoid arthritis: Back to the future?
Moreland, L. W., & O’Dell, J. R. (2002) · Arthritis & Rheumatism · doi:10.1002/art.10567 · Cited by 107
Glucocorticoids in the treatment of early and late RA
Bijlsma, J. W. J., Boers, M., Saag, K. G., & Furst, D. E. (2003) · Annals of the Rheumatic Diseases · doi:10.1136/ard.62.11.1033 · Cited by 101
Landewé, R., Geusens, P., Boers, M., van der Heijde, D. M. F. M., Lems, W. F., Koppele, J. M. T., van der Linden, S., & Garnero, P. (2004) · Arthritis & Rheumatism · doi:10.1002/art.20222 · Cited by 98
Hansen, M., Pødenphant, J., Florescu, A., et al. (1999) · Annals of the Rheumatic Diseases · doi:10.1136/ard.58.11.713 · Cited by 96
Saag, K. G., Criswell, L. A., Sems, K. M., Nettleman, M. D., & Kolluri, S. (1996) · Arthritis & Rheumatism · doi:10.1002/art.1780391107 · Cited by 96
FUNCTIONAL ASSESSMENT OF EARLY RHEUMATOID ARTHRITIS
Eberhardt, K., Svensson, B., & MORITZ, U. (1988) · Lara D. Veeken · doi:10.1093/rheumatology/27.5.364 · Cited by 95
Self-citationModerate-term, low-dose corticosteroids for rheumatoid arthritis
Criswell, L. A., Saag, K. G., Sems, K. M., Welch, V. A., Shea, B., Wells, G. A., & Suarez-Almazor, M. E. (1998) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd001158 · Cited by 73
for the LDPT-Study Group, Rau, R., Wassenberg, S., & Zeidler, H. K. (2000) · Zeitschrift für Rheumatologie · doi:10.1007/s003930070026 · Cited by 57
Self-citationA randomised placebo controlled 12 week trial of budesonide and prednisolone in rheumatoid arthritis
Kirwan, J., Hällgren, R., Mielants, H., Wollheim, F. A., Bjorck, E., Persson, T., Book, C., Bowman, S., Byron, M., Cox, N., et al. (2004) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2003.008573 · Cited by 53
Paulus, H. E., Primeo, D. D., Sanda, M., et al. (2000) · PubMed · Cited by 30
Cited by
2015 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis
Singh, J. A., Saag, K. G., Bridges, S. L., Akl, E. A., Bannuru, R. R., Sullivan, M. C., Vaysbrot, E., McNaughton, C., Osani, M., Shmerling, R. H., et al. (2016) · Arthritis & Rheumatology · doi:10.1002/art.39480 · Cited by 2,777
Singh, J. A., Furst, D. E., Bharat, A., Curtis, J. R., Kavanaugh, A. F., Kremer, J. M., Moreland, L. W., O'Dell, J., Winthrop, K. L., Beukelman, T., et al. (2012) · Arthritis Care & Research · doi:10.1002/acr.21641 · Cited by 1,789
Smolen, J. S., Landewé, R., Breedveld, F. C., Buch, M., Burmester, G., Dougados, M., Emery, P., Gaujoux-Viala, C., Gossec, L., Nam, J., et al. (2014) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2013-204573 · Cited by 1,763
Self-citation2015 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis
Singh, J. A., Saag, K. G., Bridges, S. L., Akl, E. A., Bannuru, R. R., Sullivan, M. C., Vaysbrot, E., McNaughton, C., Osani, M., Shmerling, R. H., et al. (2016) · Arthritis Care & Research · doi:10.1002/acr.22783 · Cited by 1,107
Klareskog, L., Catrina, A. I., & Paget, S. (2009) · The Lancet · doi:10.1016/s0140-6736(09)60008-8 · Cited by 787
Metadata
- Authors
- Svensson, B., Boonen, A., Albertsson, K., van der Heijde, D., Keller, C., Hafström, I., & for the BARFOT Study Group
- Venue
- Arthritis & Rheumatism
- Publisher
- Wiley
- Published
- 2005-10-27
- Volume
- 52
- Issue
- 11
- Pages
- 3360-3370
- ISSN
- 0004-3591 (ISSN-L)
- 1529-0131
- OpenAlex
- W2084911737
- Cited by
- 349
- References
- 36
- FWCI
- 11.27
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.